According to filings with the U.S. Securities and Exchange Commission, Juvena Therapeutics is raising up to $41,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Juvena Therapeutics
Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize tissue restorative biologics to treat myopathies and metabolic diseases. We are achieving this through a fully integrated, end-to-end artificial intelligence-enabled platform that combines a diverse protein library, in silico mapping of secreted proteins to specific disease phenotypes, in vitro human cell screening, in vivo pharmacology, and protein engineering capabilities.

To learn more about Juvena Therapeutics, visit https://www.juvenatherapeutics.com/
Juvena Therapeutics Linkedin Page: https://www.linkedin.com/company/juvena-therapeutics/

Contact:
Hanadie Yousef, Chief Executive Officer
914-560-6536
https://www.linkedin.com/in/hanadie-yousef-a2120026/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.